References
- Ferreira I, Datir R, Papa G, et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. bioRxiv. 2021:2021.05.08.443253. DOI:https://doi.org/10.1101/2021.05.08.443253.
- Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature [Internet]. 2021;596:273–275.
- Ranjan R, Sharma A, and Verma MK. Characterization of the second wave of COVID-19 in India. medRxiv. 2021:2021.04.17.21255665. DOI:https://doi.org/10.1101/2021.04.17.21255665
- Cherian S, Potdar V, Jadhav S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv. 2021:2021.04.22.440932. DOI:https://doi.org/10.1101/2021.04.22.440932.
- Kumar A, Parashar R, Kumar S, et al. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. J Med Virol [Internet]. 2021;n/a. DOI:https://doi.org/10.1002/jmv.27467.
- Thakur V, Bhola S, Thakur P, et al. Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection [Internet]. 2021. DOI:https://doi.org/10.1007/s15010-021-01734-2.
- Yeung J, Suri M. There are at least 200 known cases of the Delta Plus coronavirus variant worldwide. Here’s what we know [Internet]. CNN Heal. [cited 2021 Nov 28]. p. Updated 0209 GMT (1009 HKT) June 26, 2021. Available from: https://edition.cnn.com/2021/06/25/health/delta-plus-variant-explainer-intl-hnk-scn/index.html
- Raman R, Patel KJ, Ranjan KCOVID-19. Unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies. Biomolecules. 2021;12:11.
- Arora P, Kempf A, Nehlmeier I, et al. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cell Mol Immunol [Internet]. 2021;18:2557–2559.
- Kannan SR, Spratt AN, and Cohen AR, et al. Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021;124:102715.
- Explained: what is Covid-19 delta plus variant [Internet]. Times of India; 2021 [cited 2021 Nov 26]. p. Updated: Jun 25, 2021, 18:49 IST. Available from: https://timesofindia.indiatimes.com/india/explained-what-is-covid-19-delta-plus-variant/articleshow/83840705.cms
- Jeong M. Delta plus variant of SARS-CoV-2: how does it compare with the delta variant? [Internet]. 2021 [cited 2021 Nov 28]. Available from: https://www.medicalnewstoday.com/articles/delta-plus-variant-of-sars-cov-2-how-does-it-compare-with-the-delta-variant
- Solo P, and Doss MA. Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: in silico studies of medicinal plants of North-East India. Curr Res Pharmacol Drug Discov [Internet]. 2021;2:100065. Available from: https://www.sciencedirect.com/science/article/pii/S2590257121000523
- Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021;596:276–280.
- Davis C, Logan N, Tyson G, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. medRxiv [Internet]. 2021;2021.06.23.21259327. Available from: http://medrxiv.org/content/early/2021/06/28/2021.06.23.21259327.abstract
- Wang B, Goh YS, Fong S-W, et al. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. Lancet Reg Heal – West Pacific [Internet]. 2021;15. Available from: https://doi.org/https://doi.org/10.1016/j.lanwpc.2021.100276
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med [Internet]. 2021;385:585–594.
- Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv [Internet]. 2021:2021.08.18.21262237. Available from: http://medrxiv.org/content/early/2021/08/24/2021.08.18.21262237.abstract
- Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of delta plus, lambda, and other variants. bioRxiv [Internet]. 2021:2021.09.13.460163. Available from: http://biorxiv.org/content/early/2021/09/14/2021.09.13.460163.abstract
- Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med [Internet]. 2021;27:2108–2110.
- WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern [Internet]. [cited 2021 Nov 30]. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
- Basu D, Chavda VP, and Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr Res Pharmacol Drug Discov [Internet]. 2022;100086. Internet: https://www.sciencedirect.com/science/article/pii/S2590257122000062.
- Callaway E. Heavily mutated Omicron variant puts scientists on alert [Internet]. Nat News. 2021 [cited 2021 Nov 30];600:21. p. Update 27 November 2021. Available from: https://www.nature.com/articles/d41586-021-03552-w.
- Variant Technical Group (UK Health Security Agency). SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036501/Technical_Briefing_29_published_26_November_2021.pdf.
- Kumar S, Thambiraja TS, Karuppanan K, et al. Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein. bioRxiv [Internet]. 2021;2021.12.02.470946. Available from: http://biorxiv.org/content/early/2021/12/03/2021.12.02.470946.abstract
- Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv [Internet]. 2022:2021.12.30.21268495. Available from: http://medrxiv.org/content/early/2022/01/02/2021.12.30.21268495.abstract
- Flemming A. Omicron, the great escape artist. Nat Rev Immunol [Internet]. 2022;22:75.
- Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect [Internet]. 2021:1–18. Available from: https://doi.org/https://doi.org/10.1080/22221751.2021.2023329
- Chavda VP, and Apostolopoulos V. Omicron Variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly? Maturitas [Internet]. 2022; Internet: https://doi.org/10.1016/j.maturitas.2022.01.011.
- Chavda VP, Kapadia C, and Soni S, et al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy [Internet]. 2022; Internet: https://doi.org/10.2217/imt-2021-0168
- Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell [Internet]. 2022;185:457–466.e4.